EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of HBe antigen-positive chronic hepatitis B



Treatment of HBe antigen-positive chronic hepatitis B



Seminars in Liver Disease 23(1): 69-80



Spontaneous loss of hepatitis B e antigen (HBeAg) followed by seroconversion to anti-HBe usually coincides with normalization of serum alanine aminotransferase (ALT) levels, reduction in HBV DNA in serum (< 1 x 10(6) copies/mL), and a marked reduction in hepatic inflammation. Licensed antiviral therapies are the interferon (IFN) alphas and the nucleoside analogue lamivudine. Both drugs enhance the rate at which HBeAg seroconversion takes place and thus reduce progression of disease. These therapeutic agents are ineffective if given when there is no ongoing hepatitis (i.e., normal ALT), and their efficacy is greatest in individuals with the most active disease. The effectiveness of these two classes of drugs is similar, and it is possible that the two therapies combined are more effective than monotherapy with either drug. A high side-effect profile and the high risk of further morbidity when given to patients with decompensated disease limit the use of IFN-alpha. When prescribing lamivudine, drug resistance that increases with duration of therapy and the potential risk of a severe flare of hepatitis with sudden cessation of therapy, probably greatest in patients with cirrhosis, are realistic concerns. Both patient and physician need to recognize the need for close monitoring both during and after cessation of any antiviral therapy for hepatitis B.

(PDF same-day service: $19.90)

Accession: 035980437

Download citation: RISBibTeXText

PMID: 12616452

DOI: 10.1055/s-2003-37588



Related references

Interferon treatment in hepatitis B surface antigen-positive hepatitis B e antibody-positive chronic hepatitis B: role of hepatitis B core antibody IgM titre in patient selection and treatment monitoring. Journal of Viral Hepatitis 5(1): 61-66, 1998

Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 52(4): 1251-1257, 2010

Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog. Journal of Gastroenterology and Hepatology 27(3): 481-486, 2012

Association of on-treatment serum hepatitis B surface antigen level with sustained virological response to nucleos(t)ide analog in patients with hepatitis B e-antigen positive chronic hepatitis B. Hepatology Research 43(3): 219-227, 2012

Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-alpha-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B. Hepatology Research 40(4): 269-277, 2010

Direct detection of hepatitis b virus dna in human serum of hepatitis b surface antigen positive hepatitis b e antigen positive and hepatitis b surface antigen positive anti hepatitis b e antigen antibody carriers by a simplified molecular hybridization test. Hepatology 2(5): 723, 1982

Quantitative hepatitis B surface antigen combined with hepatitis B e antigen as sustained virological response predictors during extended therapy with Peginterferon alfa-2a for hepatitis B e antigen-positive chronic hepatitis B. Journal of Clinical Virology 72: 88-94, 2016

Immunosuppressive treatment of hepatitis b surface antigen positive chronic liver disease significance of hepatitis b e antigen. Hepatology 5(1): 47-49, 1985

Treatment of hepatitis b antigen positive and hepatitis b antigen negative chronic active liver disease. Digestion 16(4): 357, 1977

Correlation of the e antigen antibody system with intra hepato cellular hepatitis b core antigen and hepatitis b surface antigen in hepatitis b surface antigen positive acute and chronic liver diseases and healthy hepatitis b surface antigen carriers. Digestion 14(5/6): 488, 1976

Serum levels of hepatitis b surface and core antigen during immuno suppressive treatment of hepatitis b surface antigen positive chronic active hepatitis. Lancet 2(8191): 395-397, 1980

Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment. Antimicrobial Agents and ChemoTherapy 59(7): 4121-4128, 2016

Hepatitis b e antigen hepatitis b e antibody system in the acute phase of hepatitis b surface antigen positive hepatitis as a predictive test of developing chronic hepatitis. Bollettino dell'Istituto Sieroterapico Milanese 60(6): 468-479, 1981

Levamisole treatment of acute viral hepatitis and hepatitis b surface antigen positive chronic active hepatitis. Acta Medica Academiae Scientiarum Hungaricae 37(3): 269-282, 1980

Successful treatment of hepatitis b surface antigen and hepatitis b e antigen positive chronic liver disease prolonged inhibition of viral replication by highly soluble adenine arabinoside 5' mono phosphate. Gut 23(9): 717-723, 1982